Histone Deacetylase Inhibitors as Cancer Therapeutics PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Histone Deacetylase Inhibitors as Cancer Therapeutics PDF full book. Access full book title Histone Deacetylase Inhibitors as Cancer Therapeutics by Steven Grant. Download full books in PDF and EPUB format.
Author: Steven Grant
Publisher: Academic Press
ISBN: 0123943876
Category : Business & Economics
Languages : en
Pages : 290
Get Book Here
Book Description
Provides information on the exciting and fast-moving field of cancer research.
Author: Steven Grant
Publisher: Academic Press
ISBN: 0123943876
Category : Business & Economics
Languages : en
Pages : 290
Get Book Here
Book Description
Provides information on the exciting and fast-moving field of cancer research.
Author:
Publisher: Academic Press
ISBN: 0123946085
Category : Medical
Languages : en
Pages : 289
Get Book Here
Book Description
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. This thematic volume looks at "Histone Deacetylase Inhibitors as Cancer Therapeutics." Provides invaluable information on the exciting and fast-moving field of cancer research This thematic volume looks at "Histone Deacetylase Inhibitors as Cancer Therapeutics" Outstanding and original reviews
Author: Shabir Ahmad Ganai
Publisher: Springer Nature
ISBN: 9811581797
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Author: Christiane Pienna Soares
Publisher: Frontiers Media SA
ISBN: 2889668355
Category : Science
Languages : en
Pages : 260
Get Book Here
Book Description
Author: Henri Lichenstein
Publisher:
ISBN:
Category :
Languages : en
Pages : 26
Get Book Here
Book Description
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN.RTM. (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Author: Julia Gajer
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Shabir Ahmad Ganai
Publisher: Springer
ISBN: 9811380198
Category : Medical
Languages : en
Pages : 93
Get Book Here
Book Description
This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors’ therapeutic efficacy against various neurological complications.
Author: Eric Verdin
Publisher: Springer Science & Business Media
ISBN: 1588294994
Category : Medical
Languages : en
Pages : 349
Get Book Here
Book Description
Histone deacetylase 1 / Dominique Meunier and Christian Seiser -- Biochemistry of multiprotein HDAC complexes / Alejandro Vaquero, Michael Scher, and Danny Reinberg -- The biology of HDAC3 / Edward Seto -- The biology of HDAC8, a unique class I histone deacetylase / David Waltregny and Vincent Castronovo -- Regulation of muscle gene expression by histone deacetylases / Timothy A. McKinsey and Eric N. Olson -- The class IIA histone deacetylases: functions and regulation / Herbert G. Kasler and Eric Verdin -- Histone deacetylases in the response to misfolded proteins / J. Andrew McKee and Tso-Pang Yao -- Evolution of sirtuins from archaea to vertebrates / Roy A. Frye -- Structure of the Sir2 family of NAD+-dependent histone/protein deacetylases / Kehao Zhao and Ronen Marmorstein -- The enzymology of Sir2 proteins / Margie T. Borra and John M. Denu -- The class III protein deacetylases: homologs of yeast Sir2P / Bjoern Schwer ... [et al.] -- HDAC inhibitors: discovery, development, and clinical impacts / Akihiro Ito, Norikazu Nishino, and Mitsuaki Yoshida -- Cell cycle targets of histone deacetylase inhibitors / Brian Gabrielli -- HDAC inhibitors: an emerging anticancer therapeutic strategy / Paul Kwon, Meier Hsu, Dalia Cohen, and Peter Atadja.
Author: Avineesh Singh
Publisher: LAP Lambert Academic Publishing
ISBN: 9783845417752
Category :
Languages : en
Pages : 80
Get Book Here
Book Description
Leukemia is a type of cancer caused by the acquisition of gene mutations that bestow deregulated proliferation, impaired differentiation. There is continuing interest to recognize the signaling pathways and genes that play a crucial function in carcinogenesis and the development of resistance to antitumor drugs. The histone deacetylases (HDACs) has been found to interact with many partners through complex molecular mechanism leading to the regulation of gene expression, they have obtained the interest of a large number of researchers. Several HDAC inhibitors (HDACis) have been confirmed to proficiently protect against the growth of tumor cells in vitro as well as in vivo. Thus it is expected that some of the HDACi could be potential effective anti-leukemic drugs. In this book, we have summarized the current status of different classes of HDACs, epigenesis, apoptosis and role of HDAC inhibitors in therapeutics for the treatment of different types of leukemia.
Author: Shambhunath Choudhary
Publisher:
ISBN:
Category :
Languages : en
Pages : 221
Get Book Here
Book Description
Activating mutations of ras genes are frequently found in human cancers. Since Ras proteins and their functions play an important role in tumorigenesis, it is important to develop targeted anticancer therapeutics against Ras-related human cancers. We observed that in addition to tumorigenic ability, oncogenic H-Ras possesses a novel proapoptotic ability to facilitate the induction of apoptosis by histone deacetylase inhibitors (HDACIs), such as FR901228 and trichostatin A (TSA). HDACIs make up a new class of structurally diverse anticancer agents and have been shown to exhibit antimetastatic and antiangiogenic activities toward malignantly transformed cells. We detected that expression of oncogenic H-Ras potentiated intracellular reactive oxygen species (ROS) in human and mouse cells to enhance HDACI-induced ROS, thereby contributing to the induction of selective apoptosis and caspase activation. The first part (Part I) of this dissertation focuses on the understanding of Ras proteins, their role in normal and transformed cell physiology, and current treatment options against Ras-related human cancers, as well as the role of HDACIs and ROS in anticancer therapeutics. The next three parts (Part II-IV) focus on revealing the mechanisms for the novel pro-apoptotic ability of oncogenic H-Ras that allow HDACIs to induce selective apoptosis of the oncogenic H-Ras expressing cells. Results in Part II & III verify the pro-apoptotic activity of oncogenic H-Ras in the increased susceptibility of human cancer cells to HDACIs. The caspase pathways, the B-Raf and extracellular signal regulated kinase pathway, p21[superscript Cip]1 and p27[superscript Kip]1, and core histone contents are regulated differently by FR901228 in oncogenic H-Ras-expressed cells than their counterparts in parental cells, contributing to the increased susceptibility to the induction of selective apoptosis. Results in Part IV describe the role of reactive oxygen species in the pro-apoptotic ability of oncogenic H-Ras to enhance the cell susceptibility to HDACIs. Intracellular ROS was cooperatively up-regulated by oncogenc H-Ras and HDACI treatment to induce selective apoptosis of oncogenic H-Ras-expressing cells. The last section (Part V) summarizes the findings with their importance and discusses future directions.